The Premium of a Big Pharma License Deal
Source: Nature Biotechnology, 32, 617–619, (2014), Published online 08 July 2014 Our good friends at Venture Valuation published an interesting study in the July issue of Nature Biotechnology. In…
Source: Nature Biotechnology, 32, 617–619, (2014), Published online 08 July 2014 Our good friends at Venture Valuation published an interesting study in the July issue of Nature Biotechnology. In…
Do you know which are the top branded drug products in India? We didn't until we found this handy chart and article. We took their IMS data a step…
We're actively seeking guest bloggers for LacertaBio.com! The ideal guest blogger: Is currently involved in business development and licensing Currently works for a pharma, biotech, VC, PE, or consultancy Is…
A quick search resulted in several recent examples of US-based pharma companies executing “inversions” to reduce taxes via the acquisition of companies in Ireland: Salix merges with Cosmo Technologies, the…
We're back and knee-deep in BIO2014 follow up work. Lacerta Bio was joined by 15,665 other "industry leaders" in days full of partnering discussions, pen-grabbing, eating and drinking, and…